Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
-Poster Presentation at the Thematic Poster Session- SHANGHAI and NEW YORK, June 8, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for...
-Poster Presentation at the Thematic Poster Session- SHANGHAI and NEW YORK, June 8, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.